期刊
NEUROSCIENCE LETTERS
卷 471, 期 2, 页码 94-99出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2010.01.018
关键词
Levetiracetam; IL-1 beta; Epilepsy; Astroglia; Microglia; Gliogenesis; Hippocampus; Piriform cortex
资金
- Ministry of Education, Science and Technology [2009-0093812]
Levetiracetam (LEV, 2S-(oxo-1-pyrrolidinyl)butanamide, Keppra (R), UCB Pharma) is a new anti-epileptic drug used to treat certain types of seizures in epilepsy patients. However, the pharmacodynamics of LEV is still controversial. Recently, interleukin-1 beta (IL-1 beta) has been reported to involve in epileptic phenomena. Therefore, we investigated the effects of LEV on IL-1 beta system in the hippocampus and piriform cortex of chronic epileptic rats. As compared to controls, typical reactive astrogliosis and microgliosis were observed in the hippocampus and piriform cortex of epileptic animals. In addition, both reactive astrocytes and reactive microglia showed strong IL-1 beta and interleukin-1 receptor subtype 1 (IL-1R1) immunoreactivities. LEV reduced reactive gliosis and expression levels of IL-1 beta system in the hippocampus and the piriform cortex, while valproic acid did not. These findings suggest that the LEV may have, at least in part, anti-inflammatory effect, particularly against IL-1 beta system in neuroglia within epileptic brains. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据